Rongchang Biotech responded: The decrease in expected value due to the non-promotion of the indication of Vedolizumab (RC48) led to a devaluation of 200 million US dollars by the partner Pfizer. The overseas rights of this drug were authorized to ADCleading company Seagen in August 2021 and later acquired by Pfizer. Currently, Pfizer is promoting the indication of Vedolizumab for urothelial carcinoma overseas.

On December 28th, Jin10 Data reported that on December 27th, Daiichi Sankyo announced that the targeted TROP2 antibody conjugate drug (ADC) DATROWAY® (decarbazine monoclonal antibody), jointly developed by the company and AstraZeneca, has been approved in Japan for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative (IHC 0, IHC 1+ or IHC treated with chemotherapy.